ErbB2/Her2 antibody (pTyr1112)
-
- Target See all ErbB2/Her2 Antibodies
- ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))
-
Binding Specificity
- pTyr1112
-
Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This ErbB2/Her2 antibody is un-conjugated
-
Application
- Western Blotting (WB), Dot Blot (DB)
- Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
- Immunogen
- This ErbB2 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y1112 of human ErbB2.
- Clone
- RB40063
- Isotype
- Ig Fraction
- Top Product
- Discover our top product ErbB2/Her2 Primary Antibody
-
-
- Application Notes
- WB: 1:2000. DB: 1:500
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Expiry Date
- 6 months
-
-
Clinical relevance of HER-2/neu expression in germ-cell testicular tumors." in: Anticancer research, Vol. 24, Issue 4, pp. 2219-24, (2004) (PubMed).
: "Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?" in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, Vol. 10, Issue 3, pp. 271-6, (2004) (PubMed).
: "Lung cancer: intragenic ERBB2 kinase mutations in tumours. ..." in: Nature, Vol. 431, Issue 7008, pp. 525-6, (2004) (PubMed).
: "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2." in: Cancer cell, Vol. 6, Issue 3, pp. 251-61, (2004) (PubMed).
: "Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, Issue 29, pp. 10715-20, (2004) (PubMed).
: "
-
Clinical relevance of HER-2/neu expression in germ-cell testicular tumors." in: Anticancer research, Vol. 24, Issue 4, pp. 2219-24, (2004) (PubMed).
-
- Target
- ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))
- Alternative Name
- ERBB2 (ErbB2/Her2 Products)
- Synonyms
- CD340 antibody, HER-2 antibody, HER-2/neu antibody, HER2 antibody, MLN 19 antibody, NEU antibody, NGL antibody, TKR1 antibody, Erbb-2 antibody, Neu antibody, c-erbB2 antibody, c-neu antibody, mKIAA3023 antibody, wu:fv70f10 antibody, zgc:63601 antibody, erb2 antibody, erb-b2 receptor tyrosine kinase 2 antibody, ERBB2 antibody, Erbb2 antibody, erbb2 antibody
- Background
- ErbB2 is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors.
- Molecular Weight
- 137910
- NCBI Accession
- NP_001005862, NP_004439
- UniProt
- P04626
- Pathways
- RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development
-